Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Notes Payables (2024 - 2025)

HCW Biologics (HCWB) has disclosed Notes Payables for 2 consecutive years, with $6.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Notes Payables rose 7.36% year-over-year to $6.8 million, compared with a TTM value of $6.8 million through Sep 2025, up 7.36%, and an annual FY2024 reading of $6.3 million, changed N/A over the prior year.
  • Notes Payables was $6.8 million for Q3 2025 at HCW Biologics, up from $6.4 million in the prior quarter.
  • Across five years, Notes Payables topped out at $6.8 million in Q3 2025 and bottomed at $6.2 million in Q1 2025.